

Multi-layered genetic approaches to identify approved drug targets

Marie C. Sadler^{1,2,3,*}, Chiara Auwerx^{1,2,3,4}, Patrick Deelen^{5,6}, Zoltán Kutalik^{1,2,3,*}

¹University Center for Primary Care and Public Health, Lausanne, Switzerland

²Swiss Institute of Bioinformatics, Lausanne, Switzerland

³Department of Computational Biology, University of Lausanne, Lausanne, Switzerland

⁴Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland

⁵University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, The Netherlands

⁶Onco Institute, Utrecht, The Netherlands

*Corresponding author: marie.sadler@unil.ch, zoltan.kutalik@unil.ch

Abstract

Drugs targeting genes that harbor natural variations associated with the disease the drug is indicated for have increased odds to be approved. Various approaches have been proposed to identify likely causal genes for complex diseases, including gene-based genome-wide association studies (GWAS), rare variant burden tests in whole exome sequencing studies (Exome) or integration of GWAS with expression/protein quantitative trait loci (eQTL-GWAS/pQTL-GWAS). Here, we compare gene-prioritization approaches on 30 common clinical traits and benchmarked their ability to recover drug target genes defined using a combination of five drug databases. Across all traits, the top prioritized genes were enriched for drug targets with odds ratios (ORs) of 2.17, 2.04, 1.81 and 1.31 for the GWAS, eQTL-GWAS, Exome and pQTL-GWAS methods, respectively. We quantified the performance of these methods using the area under the receiver operating characteristic curve as metric, and adjusted for differences in testable genes and data origins. GWAS performed significantly better (54.3%) than eQTL (52.8%) and pQTL-GWAS (51.3%), but not significantly so against the Exome approach (51.7% vs 52.8% for GWAS restricted to UK Biobank data). Furthermore, our analysis showed increased performance when diffusing gene scores on gene networks. However, substantial improvements in the protein-protein interaction network may be due to circularity in the data generation process, leading to the node (gene) degree being the best predictor for drug target genes (OR = 8.7, 95% CI = 7.3-10.4) and warranting caution when applying this strategy. In conclusion, we systematically assessed strategies to prioritize drug target genes highlighting promises and potential pitfalls of current approaches.

1 Introduction

2 Drugs whose targets have genetic support were found to be more likely to succeed in clinical trials [1, 2].
3 Although multiple methods have been proposed to establish such genetic support, leveraging genetic
4 data to find disease genes and ultimately drug targets has proven to be challenging [3, 4, 5, 6]. The
5 most straightforward approach maps genome-wide association studies (GWASs) signals to the closest
6 genes with more sophisticated methods incorporating linkage disequilibrium (LD) structure and gene
7 annotation information to compute gene scores [7, 8, 9]. Over the past decade, large-scale molecular
8 quantitative trait loci (mQTL) datasets facilitated the discovery of disease mechanisms and the identifi-
9 cation of potential new drug targets [10, 11, 12, 13, 14, 15]. Several methods, including Mendelian ran-
10 domization studies, transcriptome-wide association studies and colocalization methods have integrated
11 expression and protein QTL data with GWAS studies to pinpoint likely causal genes for complex traits
12 and diseases [16, 17, 18, 19, 20, 21, 22]. More recently, the availability of high-throughput sequencing
13 data enabled the discovery and analysis of rare variants and their aggregated effects to reveal gene-
14 disease associations [23, 24]. Whole exome sequencing (WES) in the UK Biobank (UKBB) showed that
15 genes prioritized this way are 3.6 times more likely to be targets of drugs approved by the Food and
16 Drug Administration (FDA) [25].

17
18 Genes prioritised by GWASs, mQTL-GWAS integration methods and WES burden tests may not be
19 drug targets themselves, but up- or downstream of those in pharmacological pathways. Propagating
20 gene prioritization scores on networks has proven to be a promising approach to identify known drug
21 target genes [26, 27, 28, 29, 30]. Starting from seed genes (i.e., prioritized disease-associated genes),
22 network connectivity can identify neighbouring genes that strongly interact with disease genes, but lack
23 a direct genetic evidence that explain their therapeutic effect. Gene networks can be derived from lit-
24 erature or high-throughput experiments and thus are prone to yield very different results when used for
25 (seed) gene score diffusion [31].

26
27 Here, we took a comprehensive approach to examine the contribution of each method component

28 to the success of drug target prioritization. First, we focused on four different approaches to **prioritise**
29 **(seed) genes**: 1) LD-aware gene score computation from the largest GWASs with full publicly available
30 summary statistics (Pascal [9]); 2) Mendelian Randomisation (MR) combining tissue-wide expression
31 QTLs and GWAS (eQTL-GWAS); 3) MR combining plasma protein QTL with GWAS (pQTL-GWAS);
32 4) UKBB WES burden tests (Exome). We then used three different networks to **diffuse the seed**
33 **gene scores**: 1) STRING protein-protein interaction (PPI) network [32]; 2) an RNA-seq co-expression
34 network [33]; 3) the FAVA network [34]. All 12 combinations of the four seed generating methods and the
35 three networks were applied to thirty traits (Figure 1) using five different reference sets of target genes
36 (DrugBank [35], Ruiz *et al.* [36], ChEMBL [37], DGIdb [38] and STITCH [39]). Overall, we provide an
37 in-depth comparison of all combinations of these approaches, identifying their respective strengths and
38 caveats.




Figure 1: Overview of the analysis workflow. **a** Three different gene prioritization methods were tested in this study. The first one uses GWAS summary statistics as input (GWAS); the second combines molecular QTL and GWAS summary statistics (QTL-GWAS): either expression QTL (eQTL) or protein QTL (pQTL) data; the third leverages individual-level whole exome sequencing (WES) data (Exome). In the GWAS method, gene p-values are based on the sum of squared SNP z-scores (T_{sum}) that follows a weighted χ_1^2 distribution. The QTL-GWAS method integrates QTL and GWAS summary statistics through Mendelian randomization (MR). MR causal effect sizes (β_{MR}) are calculated from GWAS and mQTL effect sizes (GWAS b and mQTL b, respectively) and gene scores are the corresponding p-values. The Exome method aggregates rare variants from WES data. Putative loss-of-function and missense variants with minor allele frequencies (MAF) below 1% are collapsed in burden tests which results in gene p-values. The different approaches were benchmarked for their ability to prioritize drug target genes. **b** The effect of network diffusion using three different network types and different diffusion strengths (i.e. restart parameter r) was evaluated. Drug target genes may only be prioritized following signal propagation from neighboring disease genes. **c** Diseases were linked to target genes through public drug databases: first, we used drug-indication information to connect the 30 traits to drugs and then leveraged drug-target information to link the drugs to genes. Prioritized disease genes and corresponding diffusion scores (obtained via strategies described in panel **a** and **b**) were then tested for overlap with drug target genes through Fisher's exact tests resulting in odds ratios (ORs) and through area under the receiver operating characteristic curve (AUC) values.

39 Results

40 Overview of the analysis

41 In this study, we calculated gene prioritization scores and tested their ability to identify drug targets
42 across thirty traits (Figure 1). We focused on three types of methods termed *GWAS*, *QTL-GWAS* and
43 *Exome* that allow the computation of gene scores provided genetic association data (Figure 1a).

44
45 The GWAS method takes as input GWAS summary statistics together with a matching LD reference
46 panel. Gene p-values are calculated based on the sum of squared test statistics for SNPs falling into
47 the gene region [9]. The QTL-GWAS methods integrate GWAS summary statistics with molecular QTL
48 data for the gene of interest. We calculated gene scores using i) expression QTL data (*eQTL-GWAS*)
49 from the largest available whole blood eQTL study (eQTLGen study, $n = 31,684$) as well as tissue-wide
50 eQTL data from the GTEx consortium v8 ($n = 65-573$ for 48 tissue types) and ii) protein QTL data
51 (*pQTL-GWAS*) from the largest available plasma pQTL study (deCODE study, $n = 35,559$) [14] and i.
52 Integration was done by performing Mendelian randomization (MR) analyses using either the protein

53 or transcript as exposure and the GWAS trait as outcome. If not specified otherwise, the eQTL-GWAS
54 method refers to the tissue-wide analysis in which the eQTLGen and GTEx data are combined by
55 considering the tissue for which the MR effect was the most significant (Methods). While the GWAS
56 and QTL-GWAS methods focus on common genetic variants, the Exome method considers only
57 rare variants from WES data with minor allele frequencies (MAF) below 1%. Gene scores were
58 based on gene burden tests that aggregate putative loss-of-function and missense variants, and we
59 used the resulting p-values from the WES analysis in the UKBB [25]. To allow for a fair comparison
60 with the Exome method while also exploiting disease-specific consortia GWAS summary statistics
61 with maximized case counts, we calculated gene prioritization scores for the GWAS and QTL-GWAS
62 methods using both consortia GWAS and UKBB GWAS data (Table S1-3; Methods).

63
64 Disease genes may not coincide with drug target genes, but they may be in close proximity in terms
65 of molecular interaction (Figure 1b). Through diffusion based on random walks, we leveraged network
66 connectivity to prioritize neighbours of disease genes, which may be drug targets. We tested this
67 hypothesis on three different network types: the STRING PPI network which relies on literature
68 interactions among other data types [32], a gene co-expression network based on 31,499 RNA-seq
69 samples (*CoXRNAseq*) [33], and gene co-expression network based on single cell RNA-seq and
70 proteomics data (*FAVA*) [34]. Gene prioritization scores were obtained following diffusion at six different
71 restart parameter values ($r = 0, 0.2, 0.4, 0.6, 0.8, 1$) (Methods).

72
73 Disease drug target genes were defined using public databases. Specifically, drug-disease indica-
74 tion were retrieved from DrugBank [35], Ruiz *et al.* [36], and ChEMBL [37], while drug-drug target
75 pairs originate from DGldb [38], STITCH [39], and ChEMBL [37]. Drug target enrichment analyses
76 were calculated for the following five database combinations: DrugBank/DGldb, DrugBank/STITCH,
77 Ruiz/DGldb, Ruiz/STITCH, and ChEMBL/ChEMBL.

78
79 Finally, prioritized disease genes, defined as the top 1% of genes identified through the 12 combinations

80 of gene prioritization and network diffusion methods (5% for combinations involving the pQTL-GWAS
81 method to account for the smaller set of testable genes), were then tested for enrichment with the five
82 drug target genes using Fisher's exact test (Figure 1c). Background genes were defined as all genes that
83 could be tested by the respective method, and sensitivity analyses were performed on background genes
84 testable for all methods. Second, we calculated the area under the receiver operating characteristic
85 curve (AUC) values which has the advantage of not requiring any thresholds. To compute a combined
86 enrichment score per method, we aggregate results across traits and drug databases termed overall
87 ORs or overall AUC values (Methods).

88 **Concordance of prioritized genes among gene scoring methods**

89 We first analyzed whether genes prioritized by the GWAS, QTL-GWAS and Exome methods were
90 concordant (Figure 2). For each of the thirty traits (Figure 2a), we calculated gene scores for the
91 testable autosomal protein-coding genes (GWAS: ~19,150, eQTL-GWAS: ~12,550 (blood) and ~16,250
92 (tissue-wide), pQTL-GWAS: ~1,870, Exome: ~18,800). In the tissue-wide eQTL-GWAS method, the
93 tissue with the most significant MR p-value was selected. In Figure S1, we show the proportion of genes
94 mapped to a particular tissue category. The contribution of glandular-endocrine, neural central nervous
95 system (CNS) and whole blood (eQTLGen) tissue categories were the highest (respective means of
96 15.3%, 12.8%, and 12.6% across the thirty traits; Table S4-5). Although each trait had genes mapped
97 to nearly all tissues, a few distinctive patterns could be observed: cardiac muscle tissues contributed
98 the most to atrial fibrillation (16.4%), vascular tissues the most to coronary artery disease (16.5%)
99 followed by diastolic (11.1%) and systolic (9.9%) blood pressure, and the neural CNS contributed the
100 most to schizophrenia (16.9%) and bipolar disease (16.6%).

101




Figure 2: Evaluating the concordance of prioritized genes among methods. **a** Thirty different traits/drug indications were tested in this study. **b** The top prioritized genes between pairs of methods were compared at different thresholds for each trait (legend shown in **a**). The logarithm of odds ratios (log-OR) were calculated from Fisher's exact tests. Log-ORs are only plotted for percentiles at which common genes between pairs of methods were found. Comparisons were conducted on the same background genes and same data origins (i.e., on UK Biobank GWASs for comparisons with the Exome method). Tissue-wide eQTL-GWAS gene prioritizations were considered for the comparison with the GWAS and Exome methods, and the blood-only eQTL-GWAS gene prioritization method for the comparison with the pQTL-GWAS method. **c** Spearman correlations calculated per trait between the gene significance ($-\log_{10}(p\text{-values})$) from the GWAS and tissue-wide eQTL-GWAS methods. The analysis was conducted per trait on all common genes ($\sim 16,100$) stratified into quartiles according to transcript heritability (in *cis*). **d** Spearman correlations calculated per trait between gene Mendelian randomization (MR) causal effect sizes (β_{MR}) from the blood eQTL-GWAS and pQTL-GWAS methods. The analysis was conducted on all common genes ($\sim 1,370$) stratified into quartiles according to the transcript heritability. In **c** and **d**, the boxplots bound the 25th, 50th (median, centre), and the 75th quantile. Whiskers range from minima ($Q1 - 1.5 \cdot IQR$) to maxima ($Q3 + 1.5 \cdot IQR$) with points corresponding to individual traits from **a**.

102 The concordance of prioritized genes among pairs of methods is summarized in Figure 2b. For each
103 trait, we calculated Fisher's exact tests between the top prioritized genes at thresholds ranging from the
104 top 0.1%-10% (Methods). The overlap was the highest between the GWAS and eQTL-GWAS methods.
105 At 1%, the median odds ratio (OR) was 212.2 which dropped to 51.0 and 22.1 at 5% and 10%, respec-
106 tively. The concordance between GWAS and eQTL-GWAS prioritized genes was highest for transcripts
107 with high heritabilities (Figure 2c; Methods). Similarly, the agreement between the eQTL-GWAS (whole
108 blood) and pQTL-GWAS (blood plasma) increased with increasing transcript heritabilities (Figure 2d).
109 Overall, the median ORs between these two methods was 8.5 and 4.6 at the top 5% and 10%, respec-
110 tively. The overlap of prioritized genes was the lowest with the Exome method. The top 1% GWAS vs
111 Exome and eQTL-GWAS vs Exome overlaps (based only on UKBB GWAS summary statistics), yielded
112 median ORs of 1.7 and 1.9, respectively which dropped to 1.0 at 10% for both methods.

113 **Enrichment of prioritized genes for drug targets**

114 Next, we assessed the extent to which prioritized genes overlapped with drug target genes. For
115 each trait, we conducted enrichment analyses for the GWAS, eQTL-GWAS, pQTL-GWAS and Exome
116 methods using our five definitions of drug target genes.

117

118 In Figure 3a, we show the resulting ORs for the DrugBank/DGldb database combination. Across
119 methods, genetic support for drug targets was the highest for LDL and total cholesterol (average ORs
120 of 5.99 and 6.12, respectively). Lowest enrichment ratios were obtained for neuro-psychiatric traits
121 (average OR of 1.56) and glaucoma (average OR of 1.14). The average OR across traits was 2.48,
122 2.68, 1.65, and 1.26 for the GWAS, eQTL-GWAS, Exome and pQTL-GWAS methods, respectively.
123 We explored a range of top disease gene percentiles (0.1-5%) and the corresponding ORs are
124 shown in Figure 3b. Restricting disease genes to the top 0.1% for all methods increased the average
125 ORs without changing the method ranking with average ORs of 3.68, 4.02, 2.40, and 1.44 for the
126 GWAS, eQTL-GWAS, Exome and pQTL-GWAS methods, respectively. We further analyzed whether
127 identified drug targets were the same across methods and found that prioritized drug target genes were
128 similar between GWAS and eQTL-GWAS methods (average Jaccard index of 0.39), less so between
129 eQTL-GWAS and pQTL-GWAS methods (blood tissues; average Jaccard index of 0.15) and were very
130 different from Exome identified targets (average Jaccard index of 0.06 between GWAS & Exome and
131 eQTL-GWAS & Exome methods). Average AUC values across traits were of 53.4%, 51.9%, 50.5% and
132 49.9% for the GWAS, eQTL-GWAS, Exome and pQTL-GWAS methods (Figure 3c).

133

134 While the number of drugs reported per indication was similar across databases (average of 43.9,
135 41.8 and 40.4 for Ruiz *et al.*, ChEMBL and DrugBank, respectively), the average number of reported
136 drug targets was much higher for Ruiz/STITCH (285), Ruiz/DGldb (274.8), Drugbank/DGldb (263.4)
137 and Drugbank/STITCH (244.2) than for ChEMBL/ChEMBL (24.8; Table S7). We repeated drug target
138 enrichment calculations for all drug database combinations (Figure 3d, Figure S2). The average OR
139 for the GWAS/eQTL-GWAS methods were 2.48/2.68, 2.80/2.53, 2.18/2.12, 1.78/1.61 and 1.78/1.51 for
140 Drugbank/DGldb, ChEMBL/ChEMBL, Ruiz/DGldb, Ruiz/STITCH and Drugbank/STITCH, respectively.
141 Overall, the variability in ORs across traits was the highest in the ChEMBL database (Figure 3d, Figure
142 S2), likely due to the low average number of reported drug targets which leads to very high ORs when
143 drug targets figured among the prioritized genes (e.g. for LDL and total cholesterol), but for many traits

144 drug target genes were not among prioritized genes (e.g. for type 1 diabetes, atopic dermatitis and
145 inflammatory bowel disease).

146

147 Since enrichment results can differ widely across traits and reference databases, we calculated overall
148 enrichment and AUC values across traits and drug databases, including sensitivity analyses on UKBB
149 data only and common background genes (Table S9, Figure S4; Methods). The overall ORs were 2.17
150 (UKBB: 1.72), 2.04 (UKBB: 1.67), 1.81 and 1.31 (UKBB: 1.30) for the GWAS, eQTL-GWAS, Exome and
151 pQTL-GWAS methods, respectively. There were no significant differences between these four methods
152 in terms of enrichment OR ($P_{\text{diff}} > 0.05$ including in the sensitivity analyses). Overall AUCs were 54.3%
153 (UKBB: 52.8%), 52.8% (UKBB: 51.4%), 51.7% and 51.3% (UKBB: 50.6%) for the GWAS, eQTL-GWAS,
154 Exome and pQTL-GWAS methods, respectively. Judging by the AUC values, GWAS performed signifi-
155 cantly better than eQTL-GWAS ($P_{\text{diff}} = 3.1\text{e-}5$) also when only considering testable eQTL genes ($P_{\text{diff}} =$
156 $2.9\text{e-}4$). Significantly higher AUC values were obtained for the GWAS compared to Exome on consortia
157 data ($P_{\text{diff}} = 2.2\text{e-}4$) which was no longer the case on UKBB data ($P_{\text{diff}} = 0.06$). The difference between
158 eQTL-GWAS and Exome was not significant on either dataset (P_{diff} of 0.12 and 0.77 on consortia and
159 UKBB data, respectively). The number of testable genes was much lower for the pQTL-GWAS method
160 (~1,870 genes). With this set of background genes, GWAS still scored a higher overall AUC (55.1%,
161 $P_{\text{diff}} = 2.1\text{e-}3$). No difference was observed between the pQTL-GWAS and tissue-wide or whole blood
162 eQTL-GWAS methods (P_{diff} of 0.66 and 0.87, respectively).




Figure 3: Enrichment for drug target genes. **a** Left: Barplot with odds ratios (ORs) calculated from Fisher's exact tests between drug target genes and the top 1% (5% for pQTL-GWAS) prioritized genes for the four tested methods and thirty traits, classified according to trait category. Drug target genes were defined by DrugBank/DGIdb, and only drug target genes that could be tested by the respective method were considered. The number on the right of each bar indicates the number of identified drug target genes. Right: Overlap of identified drug target genes between pairs of methods quantified through the Jaccard index. The blood-only eQTL-GWAS gene prioritization method was used for the comparison with the pQTL-GWAS method. Plots using UKBB GWASs-only are shown in Figure S3. **b** ORs at different top prioritised gene percentiles for the four methods. The plotted dots correspond to the median OR across the thirty traits, and the shaded area bounds the 10% and 90% percentiles. **c** Boxplots showing the area under the receiver operating characteristic curve (AUC) values. AUC values were calculated for each trait as indicated by the points (legend in Figure 2a) and using the same background genes and drug target definitions as in **a**. **d** ORs calculated for the five drug target definitions and for all four methods (legend in **b**). The OR was set to 1 for traits with no identified drug target genes. In **b** and **d**, the boxplots bound the 25th, 50th (median, centre), and the 75th quantile. Whiskers range from minima ($Q1 - 1.5 \cdot IQR$) to maxima ($Q3 + 1.5 \cdot IQR$) with points outside representing potential outliers.

163 **Examples of drug target prioritization ranks**

164 In Figure 4, we highlight drug targets and their gene prioritization ranks for a few examples (complete list
165 in Table S10). Major antihypercholesterolemic drug targets *PCSK9* (evolocumab, alirocumab), *HMGCR*
166 (statins) and *NPC1L1* (ezetimibe) were top ranked by all methods (except for no pQTLs being available
167 for *HMGCR* and *NPC1L1*; Figure 4a). HCN4, the target of antiarrhythmic drug dronedarone, was priori-
168 tized as a disease gene for atrial fibrillation only through the GWAS method. Although highly expressed
169 in the atrial appendage and left ventricle of the heart, no eQTL was reported for this gene (Figure 4b).
170 Several antiepileptic drugs target SCN1A which was highly prioritized by the GWAS and eQTL-GWAS
171 methods with the strongest MR effect found in the nucleus accumbens (basal ganglia) of the brain (Fig-
172 ure 4c). Antiplatelet drug dipyrimadole used in the prevention and treatment of vascular diseases such
173 as stroke and coronary artery disease is listed to target 23 genes of the *PDE* superfamily in ChEMBL.
174 Of these, four (*PDE4D*, *PDE3A*, *PDE3B*, *PDE6B*) were ranked in the top 1% by the exome method for
175 stroke (Figure 4d). None of the other methods prioritized any of these 23 genes. For coronary artery dis-
176 ease, another superfamily member (*PDE5A*) had a low ranking ($< 2\%$) for the GWAS and QTL-GWAS
177 methods, supported by solid GWAS and e/pQTL colocalisation (Figure 4e).




Figure 4: Examples illustrating drug target genes and their prioritization ranks. **a** Three drug target genes (*PCSK9* (evolocumab, alirocumab), *HMGCR* (statins) and *NPC1L1* (ezetimibe) shown in purple) for LDL cholesterol (blue box) and their prioritization ranks (top percentiles shown in parentheses) of each of the four methods (GWAS in green, eQTL-GWAS in yellow, Exome in blue and pQTL-GWAS in red). Genes that were not testable by a given method are reported as NA (no e/pQTL means that the gene was measured, but had no QTL) and a range of ranks (i.e., 1-52) indicates tied p-values. **b** Top plot shows the prioritization ranks of *HCN4*, the target of antiarrhythmic drug, dronedarone. Bottom plot shows the gene expression profile of *HCN4* across GTEx tissues (transcript per million - TPM) with “Testis”, “Heart – Atrial Appendage” and “Heart – Left Ventricle” dominating. **c** Top plot shows the prioritization ranks of *SCN1A* (Sodium Voltage-Gated Channel Alpha Subunit 1), a drug target gene of several antiepileptic drugs. Bottom plot shows Mendelian randomization (MR) effects (red dot) with 95% CI (black bars) across tissues in which there was a significant eQTL. **d** Antiplatelet drug dipyrimadole and gene prioritization ranks of its multiple drug targets (a non-exhaustive selection) of the phosphodiesterase (*PDE*) superfamily. **e** Top plot shows the gene prioritization ranks of *PDE5A*, another reported target for dipyrimadole. Bottom plot shows the regional SNP associations ($-\log_{10}(\text{p-values})$) with coronary artery disease (CAD; GWAS, green), *PDE5A* protein (pQTL, red) and *PDE5A* transcript (eQTL, yellow), respectively (red dashed lines indicate the significance thresholds of the respective SNP association, and grey shade marks the position of *PDE5A*). Bottom row illustrates the positions and strand direction of the genes in the locus.

178 Heritability and polygenicity of drug target transcripts and proteins

179 It has been shown that drug target genes are more likely to have lower residual variance intolerance
180 scores (RVIS), i.e., are less tolerant to change [1]. With the availability of large-scale eQTL and pQTL
181 data, we tested whether drug target transcript or protein levels may be less impacted by genomic
182 variations.

183
184 To this end, we compared *cis*-heritabilities and polygenicities of drug target genes versus non-drug
185 target genes that were measured in the respective studies (i.e., also those with no reported e/pQTLs;
186 Methods). We conducted the analysis per trait and for each of the five drug target gene definitions.
187 Overall, we observed that drug target genes were less heritable and more polygenic than non-drug
188 target genes pointing towards a negative selection [40] (Figure S5). This trend was less pronounced
189 for tissue-wide than for whole blood eQTLs, and was the strongest for pQTLs. Across QTL studies and
190 drug databases, the traits for which drug targets were significantly less heritable and more polygenic
191 differed substantially. However, in no scenario drug target genes were more heritable than non-drug
192 target genes on either the transcript or protein-level (at a nominally significant level). Considering drug

193 target genes defined by DrugBank/DGIdb for the plasma protein QTLs as an example: targets for traits
194 from the circulatory system were all shown to be more polygenic, and targets for psychiatric traits were
195 all less heritable at a nominally significant level.

196 **Network diffusion**

197 Finally, we assessed whether network diffusion can identify drug target genes for which there is no
198 direct genetic evidence. Gene scores from prioritization methods defined the initial distribution p_0 of
199 the diffusion process. This process is regulated by a restart parameter r where lower values result in a
200 wider diffusion (i.e., genes can be prioritized even when distant from initial disease genes; Methods).
201 The stationary distribution was calculated for six different restart parameters, ranging from no diffusion
202 ($r = 1$) to complete diffusion ($r = 0$). Since the set of testable proteins ($\sim 1,870$) is enriched for drug
203 target genes (two-sided binomial test: p -value = $1.3e-47$ for DrugBank/DGIdb; complete results in Table
204 S15; Methods) AUC values were artificially inflated upon projecting the gene scores onto the network
205 and pQTL-GWAS results are hence not discussed.

206
207 Applying diffusion using the STRING network massively boosted the overlap between the diffused
208 prioritized genes and the drug target genes (Figure 5a-b, Figure S6-7). At no diffusion, overall AUC
209 values across the thirty traits were 54.3%, 52.8% and 51.7% for the GWAS, eQTL-GWAS and Exome
210 methods, respectively, which increased to 68.9%, 67.7% and 66.9% at $r = 0.6$, and 73.5%, 72.9% and
211 72.3% at $r = 0.4$ (Figure 5a, Figure S6, Table S12). The same trend was observed when calculating
212 enrichment scores for the top 1% genes with overall ORs of 4.63, 5.21 and 5.07 at $r = 0.4$ (Figure 5b,
213 Figure S7, Table S12). On the other hand, improvements were modest when considering co-expression
214 networks. At $r = 0.6$, overall AUC values increased to 54.9%, 54.7% and 53.5% in case of the
215 CoXRNAseq network. Although small, the difference was significant compared to no diffusion (P_{diff} of
216 $5.11e-3$, $4.12e-14$ and $4.83e-5$, respectively). Overall ORs at $r = 0.6$ were 2.28, 2.04 and 1.91 which
217 were not significantly different ($P_{\text{diff}} > 0.05$) compared to no diffusion. Likewise, in the FAVA network,
218 overall AUC values at $r = 0.6$ were 55.9%, 54.2% and 53.6% (P_{diff} compared to no diffusion of $2.23e-5$,

219 3.08e-3 and 7.3e-6), and ORs 2.38, 2.02 and 1.77 ($P_{\text{diff}} > 0.05$) for GWAS, eQTL-GWAS and Exome
220 methods, respectively (Figure S6-7, Table S12-13).

221

222 We further assessed which method's AUC values benefited the most from network diffusion. To allow
223 fair comparisons with the Exome methods, we used UKBB GWAS data for the GWAS and eQTL-GWAS
224 methods. Across all diffusion parameters r , overall AUC values were significantly higher for GWAS
225 than eQTL-GWAS in the STRING and FAVA network ($P_{\text{diff}} < 4.45e-4$), but not any different in the
226 CoXRNAseq network ($P_{\text{diff}} > 0.05$). A nominally significant difference in favour of GWAS compared
227 to Exome was only observed in the STRING network at r values of 0.4, 0.6 and 0.8 (P_{diff} of 0.0262,
228 7.36e-3 and 0.0146, respectively). No statistical differences were observed between the eQTL-GWAS
229 and Exome method except for a nominally significant difference in favour of eQTL-GWAS at $r = 0.2$ in
230 the CoXRNAseq network ($P_{\text{diff}} = 0.0113$).

231

232 When investigating the network connectivity, we observed that drug target genes were significantly more
233 likely to be hub genes (Figure 5c, Figure S8). This observation was particularly strong in the STRING
234 network (mean log-degree = 13.0 vs 12.3, $P_{\text{diff}} = 6.6e-284$ for DrugBank/DGldb), but also present in the
235 co-expression networks (Δ log-degree = 0.064, $P_{\text{diff}} = 0.011$ for CoXRNAseq; Δ log-degree = 0.3, P_{diff}
236 = 6.6e-11 for FAVA). As a consequence, the network's node degree was found to be a good predictor
237 of drug targets, and the best performance was found for the network degree in STRING (overall AUC =
238 77.6%, overall OR = 8.71). Given this bias, we generated random initial disease gene scores and de-
239 termined to which extent genetically-informed p_0 distributions performed better compared to random p_0
240 distributions. Although GWAS, eQTL-GWAS and Exome methods had significantly higher AUC values
241 than random score distributions for any given r value in the STRING network ($P_{\text{diff}} < 1.62e-7$; Table S13),
242 the performance of a mildly diffused ($r = 0.8$) random score (which is unaware of the target disease) per-
243 formed significantly better than any disease gene prioritisation method without diffusion (P_{diff} of 4.18e-6,
244 3.58e-10 and 2.10e-12 compared to GWAS, eQTL-GWAS and Exome, respectively). In line with this
245 observation, the network degree was still significantly better than gene prioritization methods at $r = 0.2$

246 (P_{diff} of $8.98e-6$, $9.87e-13$ and $1.89e-11$ compared to GWAS, eQTL-GWAs and Exome, respectively).




Figure 5: Effect of network diffusion to prioritize drug target genes. **a** Boxplots showing the area under the receiver operating characteristic curve (AUC) values for each network type (STRING, CoXRNAseq and FAVA) and method at different restart parameter values r . AUC values were calculated for each of the thirty traits, and drug target genes were defined by DrugBank/DGIdb. At an r value of 1 (no network diffusion), the analysis corresponds to the results in Figure 3b, and at an r value of 0, the gene prioritization rank is simply based on the degree of the network nodes. At $r < 1$, the background genes are the genes reported in the respective network. The star next to the pQTL-GWAS method signals that the set of testable genes for this method is enriched for drug target genes and therefore higher AUC values were obtained when adding background genes with zero-valued initial scores. **b** Odds ratios (ORs) between prioritized genes (top 1%) and drug target genes for each network type and method at different r values across the thirty traits (same drug target and background genes as in **a**). The OR was set to 1 for traits with no identified drug target genes. **c** Histograms showing the degree distribution of drug target genes and non-drug target genes in each network. The difference in log-degree (Δ) and the p-values from two-sided t-tests are shown in the titles. In **a** and **b**, the boxplots bound the 25th, 50th (median, centre), and the 75th quantile. Whiskers range from minima ($Q1 - 1.5 \cdot IQR$) to maxima ($Q3 + 1.5 \cdot IQR$) with points above or below representing potential outliers.

247 **Examples of prioritized genes through network diffusion**

248 In the following, we describe several examples for which drug targets figured among the top 1% genes
249 only after network diffusion (complete list in Table S14). Amyloid-beta precursor protein (APP) targeted
250 by the monoclonal antibody aducanumab in the treatment of Alzheimer's disease was ranked 506 (top
251 2.7%) prior and 152 (top 0.8%) after diffusion on the STRING network ($r = 0.6$; Figure 6a) based on the
252 eQTL-GWAS method. Prioritization was largely influenced by its interacting neighbour Apolipoprotein E
253 (APOE) which was the top 5 ranked gene for Alzheimer's disease. Tumor necrosis factor (TNF), a drug
254 target in the treatment of inflammatory diseases such as psoriasis, was ranked 1,558 (top 8%; Exome-
255 Psoriasis) prior and 182 (top 0.98%; $r = 0.6$) post-propagation in the STRING network (Figure 6b).
256 While initially the drug target F2 (Coagulation Factor II, Thrombin) for VTE (venous thromboembolism)
257 ranked only in the top 2% it moved up to the top 1% regardless of the network used for diffusion at $r =$
258 0.6 (top 0.9%, 0.6% and 0.7% for STRONG, CoXRNAseq and FAVA, respectively). In the STRING and
259 CoXRNAseq networks, this boost could largely be attributed to the interacting fibrinogen genes (FGA,
260 FGB and FGG) that ranked in the top 0.06% (Figure 6c).




Figure 6: Examples illustrating network diffusion to prioritize drug target genes. **a** Top ten network neighbours of drug target APP (brown circle) and their prioritization values (i.e., normalized node probabilities) of the eQTL-GWAS method for Alzheimer's disease are shown before ($r = 1$) and after diffusion ($r = 0.6$) on the STRING network. **b** Same representation as in **a** showing Exome prioritization values for psoriasis and tumor necrosis factor (TNF) drug target. **c** Top ten network neighbours of drug target F2 (Coagulation Factor II, Thrombin) in the STRING, CoXRNAseq and FAVA networks. GWAS prioritization values for venous thromboembolism (VTE) are shown before ($r = 1$) and after diffusion ($r = 0.6$) on each network. In each network example (**a-c**), the drug target gene was among the top 1% prioritized genes only after diffusion at $r = 0.6$.

Discussion

261

262 We conducted a comprehensive benchmarking between different genetically informed approaches
263 (GWAS, QTL-GWAS and Exome) combined with network diffusion to prioritize drug target genes.
264 The strength of our analysis lies in the side-by-side comparison of gene prioritization methods that
265 individually have proven to be successful in identifying drug targets. Recently, methods have emerged
266 that combine multiple genetic predictors to derive an aggregate score often using machine-learning
267 techniques [27, 41, 42]. These scores demonstrated high enrichment for drug targets but reveal little
268 about underlying molecular mechanisms. Our aim was to disentangle the importance of the choice of
269 the ground truth (i.e., drug target genes), the input data (such as molecular QTLs, WES) in combination
270 with different molecular networks to highlight added benefits while also exposing weaknesses compared
271 to using GWAS data alone.

272

273 Adjusting for differences in background genes and data origins, GWAS yielded higher AUC than
274 eQTL- and pQTL-GWAS, but no significant difference was found with Exome. Genes prioritized by
275 the Exome method were different from those identified by the GWAS and QTL-GWAS methods which
276 was also reflected in the identified drug targets. While this could imply that rare- and common variant
277 genetic architectures are complementary, differences could also be due to power issues. Possibly,
278 with increased sample size the implicated genes will converge, but the extent to which they can be
279 perturbed by regulatory vs rare coding variants might remain different. Considering ORs, we lacked
280 statistical power to claim significant differences between methods since the number of drug targets

281 among top 1% prioritized genes can be very low. Overall enrichment ORs for drug targets were 2.17,
282 2.04, 1.81 and 1.31 for the GWAS, eQTL-GWAS, Exome and pQTL-GWAS methods, respectively.
283 Although ORs for the pQTL-GWAS method may seem lower, it should be noted that testable proteins
284 (i.e., proteins with pQTLs) accounted for ~10% of GWAS testable genes. On the same background
285 genes, ORs for the tissue-wide and blood-only eQTL-GWAS methods were 1.38 and 1.22, respectively.
286 For the AUC metric, no significant difference between eQTL-GWAS and pQTL-GWAS was found. In
287 the method comparisons, we considered multiple drug target gene definitions. The number of targets
288 per drug drastically differed between ChEMBL and the DGldb or STITCH databases due to differences
289 in their construct. Drug target genes in the ChEMBL database are manually curated and should not
290 contain false positives but it remains debatable whether to consider only primary or also secondary
291 target genes. For instance, ChEMBL only lists HMGCR as a drug target for statins, whereas the DGldb
292 database also includes APOA5, APOB and APOE among others. For this reason, we considered
293 different databases and present enrichment results for both broad and narrow drug target definitions,
294 as well as aggregates.

295

296 Network diffusion was beneficial for prioritizing drug target genes with weaker genetic support. A
297 remarkable increase in drug target identification was achieved when using the STRING network.
298 However, this improvement may be due to a circularity in the data generation process leading to drug
299 targets being much more likely to also be hub genes. Although genetically-informed methods performed
300 better than random distributions, the STRING network node degrees resulted in the highest AUC values
301 overall. Thus, care has to be taken when relying on literature-derived gene-gene interactions as ag-
302 gressive diffusion will point to the same drug target genes, irrespective of the disease, and the intrinsic
303 bias stemming from under- and over-studied genes may hinder the discovery of new drug targets.
304 The improvements made with co-expression networks, which do not suffer from publication/curation
305 biases, were minor in comparison. Although significant with the AUC metric, ORs were not significantly
306 increased with a diffusion of $r = 0.6$ as compared to no diffusion for any of the methods.

307

308 Among the set of measured proteins (which itself was enriched for drug target genes), protein levels of
309 drug target genes exhibited lower heritabilities and higher polygenicities than non-drug target genes.
310 The same trend, but to a lesser extent, was observed on the transcript level. Additionally, drug target
311 genes had stronger network connections than non-drug target genes, even in unbiased co-expression
312 networks. Together, these observations suggest a tendency for drug targets to be evolutionary
313 constrained and as a result are more protected from genomic perturbations.

314

315 Several limitations should be considered. First, we do not take into account directionality of therapeutic
316 and genetic effects, i.e., whether the drug is an agonist or antagonist. Although found to be less
317 performant than GWAS, QTL-GWAS methods have the advantage of specifying directionality, as
318 opposed to gene scores from the GWAS approach which ignores SNP effect directions. Second, the
319 used molecular QTL data sets cover only a small fraction of possible intermediate traits through which
320 SNPs exert their disease-inducing effects [43]. Third, we only focus on common genetic variants when
321 associating transcript and protein levels. With the advent of coupled rare variant-protein level data,
322 either from populations enriched for rare variants or sequencing data [14, 44], more powerful QTL-
323 GWAS methods are likely to emerge that combine mechanistic insights gained from QTL approaches
324 while capturing rare variant associations previously missed. Fourth, drug target data are sparse which
325 limits the statistical power in benchmarking analyses. Given the required resources to test a drug
326 target in clinical settings, focusing on top ranking genes is of most interest. This scenario is best
327 described with a threshold that defines highly prioritized genes for enrichment analyses. However,
328 ROC curves that quantify the performance at all prioritization thresholds (i.e. use all data at hand)
329 were better powered to detect subtle differences between methods. Finally, our analysis compares
330 methods using historical drug discovery data as the ground truth. This data is highly biased with
331 G-protein-coupled receptors being targets of a third of FDA-approved drugs [45]. Many other genes
332 may be effective targets, but have never been tested in clinical trials. Thus, our results may not reflect
333 how well the tested genetic approaches uncover true disease genes, but rather how well they identify
334 targets that were historically prioritized in drug development processes. Since the emergence of robust

335 GWAS, more and more clinical trials are motivated by genetically informed targets. Thus, drug tar-
336 get databases will tend to overlap better with GWAS-inspired genes, leading to artificially higher overlap.

337

338 To conclude, we systematically evaluated major gene prioritization approaches for their ability to identify
339 approved drug target genes. Our analyses highlight the power of harnessing multiple data sources
340 by capitalizing on QTLs for mechanistic insights, sequencing data for rare variant associations, GWAS
341 when molecular QTL signals are missing and network propagation to leverage gene-gene interactions.

342 **Methods**

343 **GWAS data**

344 We used the largest (to-date), publicly available GWAS summary statistics for each analyzed condi-
345 tion (Table S1). GWAS data came mostly from consortia specific to the respective disease, and were
346 often a meta-analysis comprising the UKBB. Twenty-four out of the 30 conditions were case/control
347 studies, the remaining 6 being continuous traits: diastolic and systolic blood pressure (DBP and SBP, re-
348 spectively [46]), low-density lipoprotein and total cholesterol (LDL and TC, respectively [47]), estimated
349 glomerular filtration rate (eGFR [48]) and heel bone mineral density ([47]) proxying chronic kidney dis-
350 ease (CKD) and osteoporosis, respectively. For four traits with low case count in the UK Biobank (<
351 20,000; chronic obstructive pulmonary disease (COPD), endometriosis, pneumonia and psoriasis) and
352 no large-scale GWAS meta-analysis available, we performed a meta-analysis between the UK Biobank
353 [47] and FinnGen [49] using METAL [50].

354 **GWAS gene scores**

355 We used PascalX [9, 51] to compute gene scores based on GWAS summary statistics. The software
356 takes as input GWAS p-values, gene annotations and LD structure. SNPs are assigned to genes and
357 their squared z-scores are summed. This sum, under the null, was shown to follow a weighted chi-
358 square distribution with weights being defined by the local LD structure from which gene p-values can be
359 derived [9]. We applied PascalX with default parameters (gene \pm 50 kB) on protein-coding genes using

360 the Ensembl identifiers and annotations (Ensembl GRCh37.p13 version) and the UK10K reference panel
361 [52]. Across traits, ~19,150 protein-coding genes could be tested which were ranked by their PascalX
362 p-value.

363 **Molecular QTL-GWAS gene scores**

364 We integrated molecular quantitative trait loci (QTL) and GWAS summary statistics using Mendelian
365 randomization (MR) implemented in the smr-ivw software [53, 22]. The exposure (transcript or protein
366 levels) and outcome disease were instrumented with independent genetic variants, also called instru-
367 mental variables (IVs; $r^2 < 0.01$) and used to calculate putative causal effect estimates of the exposure
368 on the outcome (β_{MR}). IVs were required to be strongly associated to the exposure ($P_{QTL} < 1e-6$) and
369 had to pass the Steiger filter ensuring no significantly stronger effect on the outcome than on the ex-
370 posure [54]. We used expression QTLs (eQTLs) from the eQTLGen consortium [13] (whole blood; $n =$
371 31,684) and tissue-specific QTLs from the GTEx v8 release [55] (European ancestry; $n = 65-573$ for 48
372 tissue types; Table S4) to estimate causal transcript-trait effects. In the eQTLGen dataset there were
373 ~12,550 protein-coding genes with at least 1 IV which increased to ~16,250 when integrating the GTEx
374 dataset. MR results from both datasets (whole blood from eQTLGen and 49 tissues from GTEx) were
375 aggregated by considering the MR causal effect with the lowest p-value across tissues (Table S4-5).
376 Protein QTLs (pQTLs) from the deCODE study [14] (whole blood; $n = 35,559$) were used to estimate
377 protein-trait causal effects with ~1,870 proteins having at least 1 IV. Prior to the analysis, e/pQTL and
378 GWAS data were harmonized, palindromic SNPs were removed as well as SNPs with an allele frequency
379 difference > 0.05 between datasets. All transcripts and proteins were mapped to Ensembl identifiers as
380 provided by eQTLGen, GTEx and deCODE.

381 **Exome gene scores**

382 We used gene burden test results computed on WES data from the UK Biobank [25]. We extracted
383 gene-trait associations based on putative loss of function (pLOF) and deleterious missense variants
384 with MAF $< 1\%$ (M3.1 nomenclature in original publication) with phenotypes matching the investigated
385 conditions as indicated in Table S2. Associations were provided for ~18,800 genes which were ranked

386 by the association p-value and retrieved by the provided Ensembl identifier.

387 **Concordance of gene scoring methods**

388 We tested whether prioritized genes were similar or dissimilar between pairs of methods. First, only
389 genes (based on Ensembl identifiers) that were common between the two tested methods were selected
390 into the gene background. Then, prioritized genes were defined at different top percentile cut-offs (0.1%,
391 0.2%, 0.5%, 1%, 2%, 3%, 5%, 7.5%, 10%). The enrichment of prioritized genes between methods was
392 quantified by a Fisher's exact test using common genes as background genes. When calculating median
393 ORs, ORs of traits for which no prioritized genes overlapped at a given percentile were set to 1.

394 **Drug target genes**

395 We extracted drug target genes from public resources by combining drug-indication and drug-target links
396 from various databases. A given disease/indication was linked to a drug if the drug was indicated to be
397 prescribed for the selected indication and subsequently, the target genes of these drugs were extracted.
398 For drug-indication pairs we consulted DrugBank, Ruiz *et al.* and ChEMBL:

- 399 • DrugBank 5.0 [35] (download: May 2022): DrugBank indications are manually curated from drug
400 labels and underwent an expert review process. Drug indications have their own DrugBank condi-
401 tion numbers and drugs their DrugBank identifiers.
- 402 • Ruiz *et al.* [36]: A drug-disease dataset was created by querying multiple sources such as the
403 Drug Repurposing Database, the Drug Repurposing Hub, and the Drug Indication Database and
404 extracting information from drug labels, DrugBank and the American Association of Clinical Tri-
405 als Database. Drug-disease pairs were filtered for FDA-approved treatment relationships. This
406 dataset uses NLM UMLS CUIDS identifiers (National Library of Medicine -Unified Medical Lan-
407 guage System Controlled Unique Identifier) for diseases and DrugBank identifiers for drugs.
- 408 • ChEMBL [37] (download: May 2022): ChEMBL drug indications are extracted from multiple
409 sources including DailyMed package inserts, Anatomical Therapeutic Chemical (ATC) classifica-
410 tion and ClinicalTrials.gov. Mapping of disease terms to Medical Subject Headings (MeSH) vocab-

411 ularly and the Experimental Factor Ontology (EFO) is done through a combination of text-mining,
412 automated mapping and manual curation/validation. Drugs are reported with ChEMBL identifiers.

413 The mapping of GWAS traits to the drug indication identifiers of the respective database is shown in
414 Table S6.

415

416 Drug target genes were extracted from the DGldb, STITCH and ChEMBL databases:

417 • Drug Gene Interaction database (DGldb) 4.0 [38] (release: January 2021): Aggregated drug-gene
418 interactions from multiple sources including DrugBank, Drug Target Commons, the Therapeutic
419 Target Database and Guide to Pharmacology. Genes were matched to Ensembl identifiers using
420 the provided gene vocabulary file. Drugs were reported through DrugBank or ChEMBL identifiers,
421 and mapping from ChEMBL to DrugBank identifiers was done with UniChem [56], using PubChem
422 IDs as intermediates.

423 • Search Tool for Interacting Chemicals (STITCH) 5.0 [39]: Aggregated drug-protein interaction
424 data from high-throughput experiments data, manually curated datasets and prediction methods.
425 Only high confidence drug-protein relationships (confidence score ≥ 700) of the type “inhibition”
426 and “activation” were considered. STITCH uses PubChem Chemical Identifiers (CID) for drugs
427 and mapping to DrugBank IDs was done through the *chemical sources* file provided by STITCH.
428 Protein Ensembl identifiers were mapped to gene Ensembl identifiers using biomaRt (GRCh37,
429 v2.50.3)[57].

430 • ChEMBL [37] (download: May 2022): ChEMBL provides drug targets which have been manually
431 curated from literature. Drug targets are identified by ChEMBL IDs with mapping to UniProt Ac-
432 cessions provided by ChEMBL. UniProt identifiers were then mapped to gene Ensembl identifiers
433 through the UniProt REST API [58].

434 In this analysis we considered drug target genes resulting from the following combinations: Drug-
435 Bank/DGldb, DrugBank/STITCH, Ruiz/DGldb, Ruiz/STITCH, and ChEMBL/ChEMBL. The number of
436 drugs and drug target genes per indication is shown in Table S7.

437 Drug target enrichment and AUC calculations

438 Enrichment for drug target genes was calculated through two-sided Fisher's exact tests. A contingency
439 table was constructed based on testable genes (i.e., background genes), with genes categorized
440 into prioritized (top 1% or 5% for the pQTL-GWAS) and drug target genes. In rare instances (i.e.,
441 pQTL-GWAS background genes and ChEMBL/ChEMBL drug targets) where diagonal values were 0,
442 these were changed to 1. If no prioritized gene coincided with a drug target gene, the resulting OR
443 was set to 1 (for visualization purposes this was not done in barplots where each trait was shown
444 individually). AUC values and standard errors were calculated using the R package pROC v1.15.3 [59].

445

446 Log-OR and AUC values (both are denoted b_i herein) were aggregated across traits and drug databases
447 ($m = 30 \cdot 5 = 150$ observations per method) as follows:

$$\bar{b} = \frac{1}{m} \sum_i^m b_i \quad (1)$$

448 with corresponding variance:

$$\text{var}(\bar{b}) = \mathbf{1}' \cdot \mathbf{S} \cdot \mathbf{R} \cdot \mathbf{S} \cdot \mathbf{1} / m^2 \quad (2)$$

449 where \mathbf{S} is a diagonal matrix of size $m \times m$ containing standard errors of b_i and \mathbf{R} is the correlation
450 matrix between drug databases and traits. This matrix was derived from the Kronecker product of the
451 drug database correlation matrix and phenotypic trait correlation matrix (Table S8). The drug database
452 correlation matrix was derived on the gene level (i.e., 1 if the gene was a drug target for any of the 30
453 traits, 0 if not) and the phenotypic trait correlation on individual-level data from the UKBB (codes in Table
454 S2). \bar{b} was referred to as the overall AUC/ log-OR (overall OR after an exponential transformation).

455

456 To calculate the statistical difference of \bar{b}_1 and \bar{b}_2 for method 1 and 2, respectively, we derived the
457 variance of the difference as follows:

$$\text{var}(\bar{b}_1 - \bar{b}_2) = \text{var}(\bar{b}_1) + \text{var}(\bar{b}_2) - 2 \cdot \text{cov}(\bar{b}_1, \bar{b}_2) \quad (3)$$

458 with $\text{cov}(\bar{b}_1, \bar{b}_2) \approx r \times (\mathbf{1}' \cdot \mathbf{S}_1 \cdot \mathbf{R} \cdot \mathbf{S}_2 \cdot \mathbf{1}/m^2)$, where r is the empirical correlation between b_1 and b_2 .

459 From the resulting z-score, a two-sided p-value was calculated.

460 **Transcript and protein level heritabilities and polygenicity**

461 Transcript and protein level heritabilities were estimated from QTL effects. Standardized QTL effects
462 ($\hat{\beta}_G$) were approximated by dividing SNP z-scores by the square root of the sample size. The corre-
463 sponding variance ($\text{var}(\hat{\beta}_G)$) equals the inverse of the sample size. The *cis* heritability (\hat{h}_{cis}^2) could then
464 be estimated by summing up effects of independent ($r^2 < 0.01$) and significant (p-value $< 1e-6$) QTLs
465 in proximity of the transcript/protein (± 500 kB) while taking into account their variance:

$$\hat{h}_{\text{cis}}^2 = \sum_i \left(\hat{\beta}_{G_i}^2 - \text{var}(\hat{\beta}_{G_i}) \right) \quad (4)$$

466 Protein heritabilities were based on the deCODE plasma protein dataset [14] and transcript heritabilities
467 for whole blood on the eQTLGen dataset [13]. Tissue-wide transcript heritabilities were based on eQTL
468 effects from the tissue in which the MR effect was the most significant [55].

469
470 To calculate the difference in heritabilities and polygenicities between drug target and non-drug target
471 genes, we considered all transcripts and proteins measured in the respective study which were classified
472 accordingly. Per trait, the difference in heritability was then calculated through a two-sided t-test. For
473 the polygenicity analysis, we considered the number of independent ($r^2 < 0.01$) and significant (p-value
474 $< 1e-6$) QTLs associated to a transcript/protein. Note that this proxy for polygenicity is biased, as
475 for less heritable omics entities we have less power to detect the independent signals, and may look
476 less polygenic. We then conducted two-sided Wilcoxon tests to determine the difference in number of
477 instrumental variables (IVs). Heritability and polygenicity tests were only performed for traits with at
478 least three drug targets within the respective set of measured transcripts/proteins. Note that in case a

479 transcript or protein was reported as measured in the study, but had no associated QTL, its heritability
480 and number of IVs were set to zero.

481 **Networks**

482 To calculate network diffusion scores, we used the following three networks:

- 483 • Search Tool for Retrieval of Interacting Genes/Proteins (STRING) v11 [32]: The protein-protein
484 (PPI) interaction network results from predictions based on genomic context information, co-
485 expression, text-mining, experimental biochemical/genetic data and curated databases (curated
486 pathways and protein-complex knowledge). Protein Ensembl identifiers were mapped to gene En-
487 sembl identifiers using biomaRt (GRCh37, v2.50.3)[57]. We use interaction confidence scores as
488 edge weights.
- 489 • CoXRNAseq [33]: This network was constructed by first performing a principal component analy-
490 sis on the gene co-expression correlation matrix of 31,499 RNA-seq samples. Reliable principal
491 components were retained from which the final network was constructed via Pearson correlations.
492 We filtered pairwise interactions to only retain those with z-scores above 4. Genes were reported
493 with Ensembl identifiers and z-scores were used as edge weights.
- 494 • Functional Associations using Variational Autoencoders (FAVA) [34]: This network is based on
495 single cell RNA-seq read-count data from the Human Protein Atlas and proteomics data from the
496 PRoteomics IDentifications (PRIDE) database. First, the high-dimensional expression data was
497 reduced into a latent space using variational autoencoders. From this latent space, the network
498 was derived via pairwise Pearson correlations. Each reported interaction has a score which we
499 use as edge weight (final network reports interactions with scores above 0.15). Protein Ensembl
500 identifiers were mapped to gene Ensembl identifiers using biomaRt.

501 A summary of network properties is given in Table S11. In all analyses, we use weighted networks, and
502 we refer to weighted node degrees (i.e., sum of edge weights linking the node of interest to adjacent
503 nodes) as node degrees.

504 **Network diffusion**

505 We calculated network diffusion scores based on Markov random walks. Starting from an initial node
506 distribution p_0 , a stationary distribution is calculated based on network connectivity. This diffusion pro-
507 cess depends on a restart parameter r which determines how often the random walker returns to the
508 initial values. Analytically, the stationary distribution (p_∞) is given by:

$$p_\infty = (I - (1 - r) \cdot W)^{-1} \cdot p_0 \quad (5)$$

509 where W is the column-normalized weighted adjacency matrix and I the identity matrix of the same
510 dimension as W [60]. The initial node distribution p_0 was determined by the squared z-scores derived
511 from the gene p-values (normalized to sum up to 1). Genes that could not be tested by a given method
512 had their initial value set to 0. Additionally, we tested the performance of network diffusion on random
513 initial distributions p_0 . For each trait, a random distribution was generated which all were different, but
514 consistent across analyses. Resulting network diffusion scores p_∞ were ranked for AUC calculations,
515 and the top 1% scored genes were used in the enrichment analyses.

516

517 Network manipulations, visualization and degree calculations were performed with the R igraph package
518 v1.3.5 [61].

519 **Enrichment of available proteins for drug targets**

520 We conducted binomial tests to verify whether the set of testable (i.e., at least 1 pQTL) and measured
521 proteins ($\sim 1,870$ and $\sim 4,450$, respectively) were enriched for drug target genes. We performed the
522 analysis on each of the five drug target definitions and proceeded as follows: 1) we extracted the number
523 of testable/measured proteins that are drug targets (“number of successes”), 2) considering all protein-
524 coding autosomal genes (19,430), we extracted those that are drug targets (“number of trials”), 3) we
525 determined the proportion of testable/measured proteins among all protein-coding genes (“expected
526 probability of success”). From these numbers, we conducted two-sided exact binomial tests (Table

527 S15).

Data availability

Whole blood expression QTLs are from the eQTLGen eQTL meta-analysis and are available at <https://www.eqtlgen.org/cis-eqtls.html>. Tissue-wide expression QTLs are from the GTEx project and are available at <https://gtexportal.org/home/datasets>. Plasma protein QTLs are from the deCODE study and are available at <https://www.decode.com/summarydata/>. Summary statistics from whole exome gene burden tests are available in the GWAS Catalog (accession IDs are in Table S2). Genetic and phenotypic data from the UK Biobank Resource are available to approved researchers. GWAS summary statistics from the UK Biobank are available at <http://www.nealelab.is/uk-biobank> and <https://pan.ukbb.broadinstitute.org>. GWAS summary statistics from FinnGen are available at https://www.finnngen.fi/en/access_results. GWAS summary statistics for multiple sclerosis (MS) are available by application from https://imgsc.net/?page_id=31. Full list of GWAS summary statistics used in this study is in Table S1-3, all of which are publicly available. UK10K individual-level data are available upon request (https://www.uk10k.org/data_access.html).

Code availability

GWAS calculations were performed with REGENIE which is available at <https://github.com/rgcgithub/regenie>. GWAS meta-analyses were performed with METAL which is available at <https://github.com/statgen/METAL>. Gene scoring was performed with the PascalX software which is available at <https://github.com/BergmannLab/PascalX>. QTL Mendelian randomization analyses were performed with the SMR-IVW software which is available at <https://github.com/masadler/smrivw>.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

MCS and ZK conceived and designed the study. MCS performed statistical analyses. PD provided guidance on statistical analyses. ZK supervised all statistical analyses. CA contributed to the collection and interpretation of pharmacological and biological data. All the authors contributed by providing advice on interpretation of results. MCS and ZK drafted the manuscript. All authors read, approved, and provided feedback on the final manuscript.

Acknowledgements

This work was supported by the Swiss National Science Foundation (310030_189147) to Z.K. This research has been conducted using the UK Biobank Resource under Application Number 16389. LD was calculated based on the UK10K data resource (EGAD00001000740, EGAD00001000741). Computations we performed on the JURA cluster of the University of Lausanne. We also would like to acknowledge the participants and investigators of the UK Biobank and FinnGen study. We thank Daniel Krefl for his help and support in implementing the PascalX software and Liza Darrous for critical reading of the draft.

References

- [1] Matthew R Nelson, Hannah Tipney, Jeffery L Painter, Judong Shen, Paola Nicoletti, Yufeng Shen, Aris Floratos, Pak Chung Sham, Mulin Jun Li, Junwen Wang, et al. The support of human genetic evidence for approved drug indications. *Nature genetics*, 47(8):856–860, 2015.
- [2] Emily A King, J Wade Davis, and Jacob F Degner. Are drug targets with genetic support twice as likely to be approved? revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. *PLoS genetics*, 15(12):e1008489, 2019.
- [3] Stacey L Edwards, Jonathan Beesley, Juliet D French, and Alison M Dunning. Beyond gwas: illuminating the dark road from association to function. *The American Journal of Human Genetics*, 93(5):779–797, 2013.

- [4] Chen Cao and John Moulton. Gwas and drug targets. *BMC genomics*, 15(4):1–14, 2014.
- [5] Vivian Tam, Nikunj Patel, Michelle Turcotte, Yohan Bossé, Guillaume Paré, and David Meyre. Benefits and limitations of genome-wide association studies. *Nature Reviews Genetics*, 20(8):467–484, 2019.
- [6] Steven Gazal, Omer Weissbrod, Farhad Hormozdiari, Kushal K Dey, Joseph Nasser, Karthik A Jagadeesh, Daniel J Weiner, Huwenbo Shi, Charles P Fulco, Luke J O'Connor, et al. Combining snp-to-gene linking strategies to identify disease genes and assess disease omnigenicity. *Nature Genetics*, pages 1–10, 2022.
- [7] Jimmy Z Liu, Allan F Mcrae, Dale R Nyholt, Sarah E Medland, Naomi R Wray, Kevin M Brown, Nicholas K Hayward, Grant W Montgomery, Peter M Visscher, Nicholas G Martin, et al. A versatile gene-based test for genome-wide association studies. *The American Journal of Human Genetics*, 87(1):139–145, 2010.
- [8] Christiaan A de Leeuw, Joris M Mooij, Tom Heskes, and Danielle Posthuma. Magma: generalized gene-set analysis of gwas data. *PLoS computational biology*, 11(4):e1004219, 2015.
- [9] David Lamparter, Daniel Marbach, Rico Rueedi, Zoltán Kutalik, and Sven Bergmann. Fast and rigorous computation of gene and pathway scores from snp-based summary statistics. *PLoS computational biology*, 12(1):e1004714, 2016.
- [10] John Lonsdale, Jeffrey Thomas, Mike Salvatore, Rebecca Phillips, Edmund Lo, Saboor Shad, Richard Hasz, Gary Walters, Fernando Garcia, Nancy Young, et al. The genotype-tissue expression (gtex) project. *Nature genetics*, 45(6):580–585, 2013.
- [11] Benjamin B Sun, Joseph C Maranville, James E Peters, David Stacey, James R Staley, James Blackshaw, Stephen Burgess, Tao Jiang, Ellie Paige, Praveen Surendran, et al. Genomic atlas of the human plasma proteome. *Nature*, 558(7708):73–79, 2018.
- [12] Lasse Folkersen, Stefan Gustafsson, Qin Wang, Daniel Hvidberg Hansen, Åsa K Hedman, Andrew Schork, Karen Page, Daria V Zhernakova, Yang Wu, James Peters, et al. Genomic and drug target

- evaluation of 90 cardiovascular proteins in 30,931 individuals. *Nature metabolism*, 2(10):1135–1148, 2020.
- [13] Urmo Vösa, Anniqe Claringbould, Harm-Jan Westra, Marc Jan Bonder, Patrick Deelen, Biao Zeng, Holger Kirsten, Ashis Saha, Roman Kreuzhuber, Harm Brugge, et al. Large-scale cis-and trans-eqtl analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. *Nature genetics*, pages 1–11, 2021.
- [14] Egil Ferkingstad, Patrick Sulem, Bjarni A Atlason, Gardar Sveinbjornsson, Magnus I Magnusson, Edda L Styrismisdottir, Kristbjorg Gunnarsdottir, Agnar Helgason, Asmundur Oddsson, Bjarni V Hall-dorsson, et al. Large-scale integration of the plasma proteome with genetics and disease. *Nature Genetics*, 53(12):1712–1721, 2021.
- [15] Benjamin B Sun, Joshua Chiou, Matthew Traylor, Christian Benner, Yi-Hsiang Hsu, Tom G Richardson, Praveen Surendran, Anubha Mahajan, Chloe Robins, Steven G Vasquez-Grinnell, et al. Genetic regulation of the human plasma proteome in 54,306 uk biobank participants. *BioRxiv*, 2022.
- [16] Claudia Giambartolomei, Damjan Vukcevic, Eric E Schadt, Lude Franke, Aroon D Hingorani, Chris Wallace, and Vincent Plagnol. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS Genet*, 10(5):e1004383, 2014.
- [17] Farhad Hormozdiari, Martijn Van De Bunt, Ayellet V Segre, Xiao Li, Jong Wha J Joo, Michael Bilow, Jae Hoon Sul, Sriram Sankararaman, Bogdan Pasaniuc, and Eleazar Eskin. Colocalization of gwas and eqtl signals detects target genes. *The American Journal of Human Genetics*, 99(6):1245–1260, 2016.
- [18] Alexander Gusev, Arthur Ko, Huwenbo Shi, Gaurav Bhatia, Wonil Chung, Brenda WJH Penninx, Rick Jansen, Eco JC De Geus, Dorret I Boomsma, Fred A Wright, et al. Integrative approaches for large-scale transcriptome-wide association studies. *Nature genetics*, 48(3):245–252, 2016.
- [19] Alvaro N Barbeira, Scott P Dickinson, Rodrigo Bonazzola, Jiamao Zheng, Heather E Wheeler, Jason M Torres, Eric S Torstenson, Kaanan P Shah, Tzintzuni Garcia, Todd L Edwards, et al.

- Exploring the phenotypic consequences of tissue specific gene expression variation inferred from gwas summary statistics. *Nature communications*, 9(1):1–20, 2018.
- [20] Yang Wu, Jian Zeng, Futao Zhang, Zhihong Zhu, Ting Qi, Zhili Zheng, Luke R Lloyd-Jones, Riccardo E Marioni, Nicholas G Martin, Grant W Montgomery, et al. Integrative analysis of omics summary data reveals putative mechanisms underlying complex traits. *Nature communications*, 9(1):1–14, 2018.
- [21] Eleonora Porcu, Sina Rüeger, Kaido Lepik, Federico A Santoni, Alexandre Reymond, and Zoltán Kutalik. Mendelian randomization integrating gwas and eqtl data reveals genetic determinants of complex and clinical traits. *Nature communications*, 10(1):1–12, 2019.
- [22] Marie C Sadler, Chiara Auwerx, Kaido Lepik, Eleonora Porcu, and Zoltán Kutalik. Quantifying the role of transcript levels in mediating dna methylation effects on complex traits and diseases. *Nature Communications*, 13(1):1–14, 2022.
- [23] Elizabeth T Cirulli, Simon White, Robert W Read, Gai Elhanan, William J Metcalf, Francisco Tanudjaja, Donna M Fath, Efren Sandoval, Magnus Isaksson, Karen A Schlauch, et al. Genome-wide rare variant analysis for thousands of phenotypes in over 70,000 exomes from two cohorts. *Nature communications*, 11(1):1–10, 2020.
- [24] Jack A Kosmicki, Julie E Horowitz, Nilanjana Banerjee, Rouel Lanche, Anthony Marcketta, Evan Maxwell, Xiaodong Bai, Dylan Sun, Joshua D Backman, Deepika Sharma, et al. Pan-ancestry exome-wide association analyses of covid-19 outcomes in 586,157 individuals. *The American Journal of Human Genetics*, 108(7):1350–1355, 2021.
- [25] Joshua D Backman, Alexander H Li, Anthony Marcketta, Dylan Sun, Joelle Mbatchou, Michael D Kessler, Christian Benner, Daren Liu, Adam E Locke, Suganthi Balasubramanian, et al. Exome sequencing and analysis of 454,787 uk biobank participants. *Nature*, 599(7886):628–634, 2021.
- [26] Emre Guney, Jörg Menche, Marc Vidal, and Albert-László Barábasi. Network-based in silico drug efficacy screening. *Nature communications*, 7(1):1–13, 2016.

- [27] Hai Fang, Hans De Wolf, Bogdan Knezevic, Katie L Burnham, Julie Osgood, Anna Sanniti, Alicia Lledó Lara, Silva Kasela, Stephane De Cesco, Jörg K Wegner, et al. A genetics-led approach defines the drug target landscape of 30 immune-related traits. *Nature genetics*, 51(7):1082–1091, 2019.
- [28] Aidan MacNamara, Nikolina Nakic, Ali Amin Al Olama, Cong Guo, Karsten B Sieber, Mark R Hurle, and Alex Gutteridge. Network and pathway expansion of genetic disease associations identifies successful drug targets. *Scientific reports*, 10(1):1–11, 2020.
- [29] Yingnan Han, Clarence Wang, Katherine Klinger, Deepak K Rajpal, and Cheng Zhu. An integrative network-based approach for drug target indication expansion. *PLoS one*, 16(7):e0253614, 2021.
- [30] Inigo Barrio-Hernandez, Jeremy Schwartzentruber, Anjali Shrivastava, Noemi del Toro, Qian Zhang, Glyn Bradley, Henning Hermjakob, Sandra Orchard, Ian Dunham, Carl A Anderson, et al. Network expansion of genetic associations defines a pleiotropy map of human cell biology. *BioRxiv*, 2021.
- [31] Katja Luck, Dae-Kyum Kim, Luke Lambourne, Kerstin Spirohn, Bridget E Begg, Wenting Bian, Ruth Brignall, Tiziana Cafarelli, Francisco J Campos-Laborie, Benoit Charloteaux, et al. A reference map of the human binary protein interactome. *Nature*, 580(7803):402–408, 2020.
- [32] Damian Szklarczyk, Annika L Gable, David Lyon, Alexander Junge, Stefan Wyder, Jaime Huerta-Cepas, Milan Simonovic, Nadezhda T Doncheva, John H Morris, Peer Bork, et al. String v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic acids research*, 47(D1):D607–D613, 2019.
- [33] Patrick Deelen, Sipko van Dam, Johanna C Herkert, Juha M Karjalainen, Harm Brugge, Kristin M Abbott, Cleo C van Diemen, Paul A van der Zwaag, Erica H Gerkes, Evelien Zonneveld-Huijssoon, et al. Improving the diagnostic yield of exome-sequencing by predicting gene–phenotype associations using large-scale gene expression analysis. *Nature communications*, 10(1):1–13, 2019.

- [34] Mikaela Koutrouli, Pau Piera Líndez, Robbin Bouwmeester, Lennart Martens, and Lars Juhl Jensen. Fava: High-quality functional association networks inferred from scrna-seq and proteomics data. *bioRxiv*, 2022.
- [35] David S Wishart, Yannick D Feunang, An C Guo, Elvis J Lo, Ana Marcu, Jason R Grant, Tanvir Sajed, Daniel Johnson, Carin Li, Zinat Sayeeda, et al. Drugbank 5.0: a major update to the drugbank database for 2018. *Nucleic acids research*, 46(D1):D1074–D1082, 2018.
- [36] Camilo Ruiz, Marinka Zitnik, and Jure Leskovec. Identification of disease treatment mechanisms through the multiscale interactome. *Nature communications*, 12(1):1–15, 2021.
- [37] Anna Gaulton, Anne Hersey, Michał Nowotka, A Patricia Bento, Jon Chambers, David Mendez, Prudence Mutowo, Francis Atkinson, Louisa J Bellis, Elena Cibrián-Uhalte, et al. The chembl database in 2017. *Nucleic acids research*, 45(D1):D945–D954, 2017.
- [38] Sharon L Freshour, Susanna Kiwala, Kelsy C Cotto, Adam C Coffman, Joshua F McMichael, Jonathan J Song, Malachi Griffith, Obi L Griffith, and Alex H Wagner. Integration of the drug–gene interaction database (dgidb 4.0) with open crowdsourcing efforts. *Nucleic acids research*, 49(D1):D1144–D1151, 2021.
- [39] Damian Szklarczyk, Alberto Santos, Christian Von Mering, Lars Juhl Jensen, Peer Bork, and Michael Kuhn. Stitch 5: augmenting protein–chemical interaction networks with tissue and affinity data. *Nucleic acids research*, 44(D1):D380–D384, 2016.
- [40] Luke J O’Connor, Armin P Schoech, Farhad Hormozdiari, Steven Gazal, Nick Patterson, and Alkes L Price. Extreme polygenicity of complex traits is explained by negative selection. *The American Journal of Human Genetics*, 105(3):456–476, 2019.
- [41] Edward Mountjoy, Ellen M Schmidt, Miguel Carmona, Jeremy Schwartzentruber, Gareth Peat, Alfredo Miranda, Luca Fumis, James Hayhurst, Annalisa Buniello, Mohd Anisul Karim, et al. An open approach to systematically prioritize causal variants and genes at all published human gwas trait-associated loci. *Nature Genetics*, 53(11):1527–1533, 2021.

- [42] Vincenzo Forgetta, Lai Jiang, Nicholas A Vulpescu, Megan S Hogan, Siyuan Chen, John A Morris, Stepan Grinek, Christian Benner, Dong-Keun Jang, Quy Hoang, et al. An effector index to predict target genes at gwas loci. *Human Genetics*, pages 1–17, 2022.
- [43] Douglas W Yao, Luke J O'Connor, Alkes L Price, and Alexander Gusev. Quantifying genetic effects on disease mediated by assayed gene expression levels. *Nature Genetics*, 52(6):626–633, 2020.
- [44] Ryan S Dhindsa, Oliver S Burren, Benjamin B Sun, Bram P Prins, Dorota Matelska, Eleanor Wheeler, Jonathan Mitchell, Erin Oerton, Ventzislava A Hristova, Katherine R Smith, et al. Influences of rare protein-coding genetic variants on the human plasma proteome in 50,829 uk biobank participants. *bioRxiv*, 2022.
- [45] Alexander S Hauser, Sreenivas Chavali, Ikuo Masuho, Leonie J Jahn, Kirill A Martemyanov, David E Gloriam, and M Madan Babu. Pharmacogenomics of gpcr drug targets. *Cell*, 172(1-2):41–54, 2018.
- [46] Evangelos Evangelou, Helen R Warren, David Mosen-Ansorena, Borbala Mifsud, Raha Pazoki, He Gao, Georgios Ntritsos, Niki Dimou, Claudia P Cabrera, Ibrahim Karaman, et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. *Nature genetics*, 50(10):1412–1425, 2018.
- [47] Clare Bycroft, Colin Freeman, Desislava Petkova, Gavin Band, Lloyd T Elliott, Kevin Sharp, Allan Motyer, Damjan Vukcevic, Olivier Delaneau, Jared O'Connell, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature*, 562(7726):203–209, 2018.
- [48] Matthias Wuttke, Yong Li, Man Li, Karsten B Sieber, Mary F Feitosa, Mathias Gorski, Adrienne Tin, Lihua Wang, Audrey Y Chu, Anselm Hoppmann, et al. A catalog of genetic loci associated with kidney function from analyses of a million individuals. *Nature genetics*, 51(6):957–972, 2019.
- [49] Mitja I Kurki, Juha Karjalainen, Priit Palta, Timo P Sipilä, Kati Kristiansson, Kati Donner, Mary P Reeve, Hannele Laivuori, Mervi Aavikko, Mari A Kaunisto, et al. Finngen: Unique genetic insights from combining isolated population and national health register data. *medRxiv*, 2022.

- [50] Cristen J Willer, Yun Li, and Gonçalo R Abecasis. Metal: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics*, 26(17):2190–2191, 2010.
- [51] Daniel Krefl and Sven Bergmann. Bergmannlab/pascalx: Pascalx v0.0.1 (v0.0.1), 2021. <https://doi.org/10.5281/zenodo.4429922>.
- [52] UK10K et al. The UK10K project identifies rare variants in health and disease. *Nature*, 526(7571):82, 2015.
- [53] Zhihong Zhu, Futao Zhang, Han Hu, Andrew Bakshi, Matthew R Robinson, Joseph E Powell, Grant W Montgomery, Michael E Goddard, Naomi R Wray, Peter M Visscher, et al. Integration of summary data from gwas and eqtl studies predicts complex trait gene targets. *Nature genetics*, 48(5):481–487, 2016.
- [54] Gibran Hemani, Kate Tilling, and George Davey Smith. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. *PLoS genetics*, 13(11):e1007081, 2017.
- [55] THE GTEx CONSORTIUM. The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science*, 369(6509):1318–1330, 2020.
- [56] Jon Chambers, Mark Davies, Anna Gaulton, Anne Hersey, Sameer Velankar, Robert Petryszak, Janna Hastings, Louisa Bellis, Shaun McGlinchey, and John P Overington. Unichem: a unified chemical structure cross-referencing and identifier tracking system. *Journal of cheminformatics*, 5(1):1–9, 2013.
- [57] Steffen Durinck, Paul T. Spellman, Ewan Birney, and Wolfgang Huber. Mapping identifiers for the integration of genomic datasets with the r/bioconductor package biomart. *Nature Protocols*, 4:1184–1191, 2009.
- [58] Andrew Nightingale, Ricardo Antunes, Emanuele Alpi, Borisas Bursteinas, Leonardo Gonzales, Wudong Liu, Jie Luo, Guoying Qi, Edd Turner, and Maria Martin. The proteins api: accessing key integrated protein and genome information. *Nucleic acids research*, 45(W1):W539–W544, 2017.

- [59] Xavier Robin, Natacha Turck, Alexandre Hainard, Natalia Tiberti, Frédérique Lisacek, Jean-Charles Sanchez, and Markus Müller. proc: an open-source package for r and s+ to analyze and compare roc curves. *BMC bioinformatics*, 12(1):1–8, 2011.
- [60] Hanghang Tong, Christos Faloutsos, and Jia-Yu Pan. Fast random walk with restart and its applications. In *Sixth international conference on data mining (ICDM'06)*, pages 613–622. IEEE, 2006.
- [61] Gabor Csardi, Tamas Nepusz, et al. The igraph software package for complex network research. *InterJournal, complex systems*, 1695(5):1–9, 2006.